Mirum Pharmaceuticals, Inc. (MIRM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MIRM SEC filings page.
Mirum Pharmaceuticals, Inc. (MIRM) reported $618.1M in revenue over the twelve months to Jun 30, 2026, up 44.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue scale is absorbing heavy operating spending, bringing Mirum near break-even while cash generation turns positive without much capital investment.
Revenue expanded from$186.4M in FY2023 to$521.3M in FY2025. Over the same span, operating margin improved from-58.6% to-4.3% despite higher SG&A and R&D, indicating fixed-cost absorption rather than a cost-cutting story.
In FY2025, operating cash flow was
The balance sheet is becoming more liability-financed: debt-to-equity was 1.7x in FY2025, while the current ratio fell from 4.5x in FY2023 to 2.7x. Current assets still exceed current liabilities, but the shrinking cushion alongside rising receivables suggests growth is consuming more working capital.
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Mirum Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Mirum Pharmaceuticals, Inc. held $391.4M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $55.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Mirum Pharmaceuticals, Inc. scores 86/100 among other emerging companies.
Mirum Pharmaceuticals, Inc. had 60M shares outstanding at the end of fiscal year 2025, against 49M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Mirum Pharmaceuticals, Inc. scores 44/100 among other emerging companies.
Mirum Pharmaceuticals, Inc. spent $186.2M on research and development in fiscal year 2025, which was 34.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Mirum Pharmaceuticals, Inc. scores 66/100 among other emerging companies.
Mirum Pharmaceuticals, Inc. reported revenue of $521.3M in fiscal year 2025, against $336.9M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Mirum Pharmaceuticals, Inc. scores 83/100 among other emerging companies.
Mirum Pharmaceuticals, Inc.'s operations generated $55.8M of cash in fiscal year 2025, against $10.3M generated in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Mirum Pharmaceuticals, Inc. scores 94/100 among other emerging companies.
Mirum Pharmaceuticals, Inc.'s cash, cash equivalents and investments came to $391.4M at the end of fiscal year 2025, against $528.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Mirum Pharmaceuticals, Inc. scores 52/100 among other emerging companies.
Mirum Pharmaceuticals, Inc. scores 5.92, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($5.3B) relative to total liabilities ($528.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Mirum Pharmaceuticals, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Mirum Pharmaceuticals, Inc. reported a net loss of $23.4M while generating $55.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Mirum Pharmaceuticals, Inc. reported an operating loss of $22.1M against $14.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Mirum Pharmaceuticals, Inc. generated $176.2M in revenue in Q2 2026. This represents an increase of 37.9% from the same quarter a year earlier. Against the prior quarter it is up 10.2%.
Mirum Pharmaceuticals, Inc.'s EBITDA was -$35.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3436.6% from the same quarter a year earlier. Against the prior quarter it is up 95.5%.
Mirum Pharmaceuticals, Inc. reported -$67.2M in net income in Q2 2026. This represents a decrease of 1047.0% from the same quarter a year earlier. Against the prior quarter it is up 91.5%.
Mirum Pharmaceuticals, Inc. earned -$1.06 per diluted share (EPS) in Q2 2026. This represents a decrease of 783.3% from the same quarter a year earlier. Against the prior quarter it is up 92.1%.
Cash & Balance Sheet
Mirum Pharmaceuticals, Inc. recorded an outflow of $44.3M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 471.6% from the same quarter a year earlier. Against the prior quarter it is up 80.7%.
Mirum Pharmaceuticals, Inc. held $330.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Mirum Pharmaceuticals, Inc.'s operating margin was -24.1% in Q2 2026, reflecting core business profitability. This is down 20.2 percentage points from the same quarter a year earlier.
Mirum Pharmaceuticals, Inc.'s net profit margin was -38.1% in Q2 2026, showing the share of revenue converted to profit. This is down 33.6 percentage points from the same quarter a year earlier.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Mirum Pharmaceuticals, Inc. invested $90.5M in research and development in Q2 2026. This represents an increase of 96.5% from the same quarter a year earlier. Against the prior quarter it is down 7.5%.
Mirum Pharmaceuticals, Inc. invested $23K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 81.7% from the same quarter a year earlier. Against the prior quarter it is down 96.5%.
Not reported for Q2 2026.
MIRM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $176.2M+37.9% | $159.9M+43.3% | $148.9M+49.8% | $133.0M+47.2% | $127.8M+64.1% | $111.6M+61.2% | $99.4M+42.9% | $90.4M+89.4% |
| R&D Expenses | $90.5M+96.5% | $97.9M+138.5% | $56.1M+27.4% | $43.0M+35.5% | $46.1M+41.0% | $41.0M+27.4% | $44.0M+42.3% | $31.7M+21.4% |
| SG&A Expenses | $81.5M+28.7% | $96.3M+66.9% | $74.1M+30.4% | $61.9M+22.5% | $63.3M+28.6% | $57.7M+26.4% | $56.8M+23.1% | $50.5M+38.4% |
| Operating Income | -$42.5M-752.6% | -$789.5M-5099.7% | -$4.6M+81.1% | $2.6M+120.5% | -$5.0M+79.4% | -$15.2M+42.6% | -$24.2M+25.7% | -$12.7M+49.6% |
| EBITDA | -$35.6M-3436.6% | -$782.6M-8470.7% | $1.5M+108.3% | $8.7M+230.7% | $1.1M+105.8% | -$9.1M+56.1% | -$18.2M+32.9% | -$6.6M+70.5% |
| Interest Expense | $2.6M-27.1% | $3.6M+0.6% | $3.6M+0.5% | $3.6M+0.6% | $3.6M+0.6% | $3.6M+0.5% | $3.6M | $3.6M+0.3% |
| Income Tax | $1.7M+320.1% | $475K-53.8% | $767K+233.2% | -$262K-175.5% | $402K-36.7% | $1.0M+64.9% | -$576K-356.0% | $347K+39.4% |
| Net Income | -$67.2M-1047.0% | -$790.2M-5283.6% | -$5.7M+75.9% | $2.9M+120.4% | -$5.9M+76.2% | -$14.7M+41.9% | -$23.8M+33.3% | -$14.2M+39.7% |
| EPS (Basic) | -$1.06-783.3% | -$13.43-4376.7% | -$0.12+75.5% | $0.06+120.0% | -$0.12+76.9% | -$0.30+44.4% | -$0.49+31.9% | -$0.30+47.4% |
| EPS (Diluted) | -$1.06-783.3% | -$13.43-4376.7% | -$0.12+75.5% | $0.05+116.7% | -$0.12+76.9% | -$0.30+44.4% | -$0.49+31.9% | -$0.30+47.4% |
| Diluted Shares (Avg) | 63M+27.4% | 59M+20.4% | N/A | 57M+19.3% | 50M+5.3% | 49M+4.2% | N/A | 48M+16.3% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
MIRM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.0B+44.0% | $890.9M+29.1% | $842.8M+25.7% | $785.1M+17.6% | $725.8M+9.8% | $690.2M+5.9% | $670.8M+3.7% | $667.9M+2.7% |
| Current Assets | $636.3M+40.3% | $569.4M+38.6% | $549.7M+39.9% | $530.6M+37.2% | $453.4M+23.3% | $410.8M+5.5% | $392.8M+1.4% | $386.6M-0.5% |
| Cash & Equivalents | $330.7M+45.0% | $324.9M+53.4% | $296.7M+33.3% | $282.0M+26.5% | $228.1M-2.2% | $211.8M-30.1% | $222.5M-22.3% | $223.0M-26.4% |
| Short-Term Investments | $107.6M+40.7% | $61.4M-6.8% | $86.6M+49.9% | $93.5M+52.1% | $76.4M+69.4% | $65.9M | $57.8M | $61.5M+1969.2% |
| Inventory | $25.8M+12.3% | $25.5M+13.8% | $24.9M+11.1% | $24.0M+11.2% | $22.9M+12.2% | $22.4M+3.8% | $22.4M+0.4% | $21.6M-2.9% |
| Accounts Receivable | $145.4M+36.1% | $133.1M+38.9% | $123.3M+57.5% | $107.1M+56.3% | $106.8M+76.8% | $95.9M+74.3% | $78.3M+15.2% | $68.5M+43.3% |
| Long-Term Investments | $123.0M+619.0% | $34.4M+64.3% | $8.1M-35.3% | $2.5M-73.5% | $17.1M+0.2% | $20.9M | $12.5M | $9.3M |
| Total Liabilities | $1.1B+124.2% | $648.4M+41.9% | $528.1M+18.6% | $493.1M+13.1% | $470.7M+9.0% | $457.0M+9.5% | $445.1M+11.9% | $435.9M+14.2% |
| Current Liabilities | $222.8M+53.9% | $272.8M+113.9% | $205.8M+62.6% | $160.4M+38.5% | $144.8M+28.9% | $127.6M+20.5% | $126.6M+45.4% | $115.8M+55.0% |
| Non-Current Liabilities | $832.6M+155.5% | $375.6M+14.0% | $322.3M+1.2% | $332.7M+3.9% | $325.9M+2.0% | $329.4M+5.8% | $318.6M+2.5% | $320.1M+4.3% |
| Total Equity | -$10.4M-104.1% | $242.5M+4.0% | $314.7M+39.5% | $292.0M+25.9% | $255.2M+11.4% | $233.3M-0.6% | $225.6M-9.3% | $232.0M-13.8% |
| Retained Earnings | -$1.5B-129.4% | -$1.5B-121.2% | -$667.5M-3.6% | -$661.8M-6.7% | -$664.7M-9.7% | -$658.9M-13.3% | -$644.2M-15.8% | -$620.4M-19.2% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
MIRM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$44.3M-467.5% | -$228.8M-11565.6% | $6.1M+219.7% | $39.7M+896.0% | $12.0M+416.6% | -$2.0M-112.9% | -$5.1M+69.5% | $4.0M+121.9% |
| Depreciation & Amortization | $6.9M+14.5% | $6.9M+13.6% | $6.1M+0.3% | $6.1M+0.1% | $6.1M+3.5% | $6.1M+6.9% | $6.1M+10.2% | $6.1M+127.5% |
| Stock-Based Compensation | $30.6M+65.6% | $36.2M+129.1% | N/A | $18.1M+52.2% | $18.5M+56.0% | $15.8M+38.0% | N/A | $11.9M+42.0% |
| Capital Expenditures | $23K-81.7% | $664K+1519.5% | $600K+2900.0% | $187K+3.3% | $126K-83.8% | $41K+215.4% | $20K | $181K |
| Free Cash Flow | -$44.3M-471.6% | -$229.4M-11359.9% | $5.5M+207.4% | $39.5M+938.5% | $11.9M+360.0% | -$2.0M-113.2% | -$5.1M+69.4% | $3.8M+120.9% |
| Investing Cash Flow | -$160.0M-2324.5% | -$11.6M+28.3% | $1.0M+56.9% | -$2.2M+87.7% | -$6.6M+90.9% | -$16.1M-124007.7% | $641K+132.1% | -$18.0M+90.1% |
| Financing Cash Flow | $211.4M+2333.7% | $270.1M+4147.2% | $9.0M+68.5% | $16.1M+316.7% | $8.7M+19.2% | $6.4M+427.7% | $5.3M+200.5% | $3.9M-98.1% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
MIRM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -24.1%-20.2pp | -493.8% | -3.1%+21.3pp | 2.0%+16.0pp | -3.9%+27.2pp | -13.6%+24.6pp | -24.4%+22.5pp | -14.0%+38.7pp |
| Net Margin | -38.1%-33.6pp | -494.2% | -3.9%+20.1pp | 2.2%+17.9pp | -4.6%+27.1pp | -13.2%+23.4pp | -23.9%+27.3pp | -15.8%+33.7pp |
| Return on Equity | N/A | -325.9%-319.6pp | -1.8%+8.7pp | 1.0%+7.1pp | -2.3%+8.5pp | -6.3%+4.5pp | -10.5%+3.8pp | -6.1%+2.6pp |
| Return on Assets | -6.4%-5.6pp | -88.7%-86.6pp | -0.7%+2.9pp | 0.4%+2.5pp | -0.8%+2.9pp | -2.1%+1.8pp | -3.5%+2.0pp | -2.1%+1.5pp |
| Current Ratio | 2.86-0.3x | 2.09-1.1x | 2.67-0.4x | 3.310.0x | 3.13-0.1x | 3.22-0.5x | 3.10-1.3x | 3.34-1.9x |
| Debt-to-Equity | N/A | 2.67+0.7x | 1.68-0.3x | 1.69-0.2x | 1.840.0x | 1.96+0.2x | 1.97+0.4x | 1.88+0.5x |
| Asset Turnover | 0.170.0x | 0.180.0x | 0.180.0x | 0.170.0x | 0.18+0.1x | 0.16+0.1x | 0.150.0x | 0.14+0.1x |
| FCF Margin | -25.1%-34.4pp | -143.5% | 3.7%+8.8pp | 29.7%+25.5pp | 9.3%+15.2pp | -1.8%-23.8pp | -5.1%+18.8pp | 4.2%+42.4pp |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. MIRM | FY2025 | $521.3M | -$23.4M | -4.5% | $5.3B | 71/100 |
| Protagonist Therapeutics, Inc PTGX | FY2025 | $46.0M | -$130.1M | N/A | $9.1B | 76/100 |
| Ascentage Pharma Group International AAPG | FY2025 | $71.4M | -$177.7M | N/A | $1.4B | 24/100 |
| Krystal Biotech, Inc. KRYS | FY2025 | $389.1M | $204.8M | 52.6% | $9.5B | 59/100 |
| Metsera, Inc. MTSR | FY2024 | N/A | -$209.1M | N/A | $7.4B | — |
| Zai Lab Limited ZLAB | FY2025 | $460.2M | -$175.5M | -38.1% | $2.7B | 64/100 |
Where Mirum Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
What is Mirum Pharmaceuticals, Inc.'s annual revenue?
Mirum Pharmaceuticals, Inc. (MIRM) reported $521.3M in total revenue for fiscal year 2025. This represents a 54.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Mirum Pharmaceuticals, Inc.'s revenue growing?
Mirum Pharmaceuticals, Inc. (MIRM) revenue grew by 54.7% year-over-year, from $336.9M to $521.3M in fiscal year 2025.
Is Mirum Pharmaceuticals, Inc. profitable?
No, Mirum Pharmaceuticals, Inc. (MIRM) reported a net income of -$23.4M in fiscal year 2025, with a net profit margin of -4.5%.
What is Mirum Pharmaceuticals, Inc.'s EBITDA?
Mirum Pharmaceuticals, Inc. (MIRM) had EBITDA of $2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Mirum Pharmaceuticals, Inc.'s operating margin?
Mirum Pharmaceuticals, Inc. (MIRM) had an operating margin of -4.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Mirum Pharmaceuticals, Inc.'s net profit margin?
Mirum Pharmaceuticals, Inc. (MIRM) had a net profit margin of -4.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Mirum Pharmaceuticals, Inc.'s return on equity (ROE)?
Mirum Pharmaceuticals, Inc. (MIRM) has a return on equity of -7.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Mirum Pharmaceuticals, Inc.'s free cash flow?
Mirum Pharmaceuticals, Inc. (MIRM) generated $54.9M in free cash flow during fiscal year 2025. This represents a 488.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Mirum Pharmaceuticals, Inc.'s operating cash flow?
Mirum Pharmaceuticals, Inc. (MIRM) generated $55.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Mirum Pharmaceuticals, Inc.'s total assets?
Mirum Pharmaceuticals, Inc. (MIRM) had $842.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Mirum Pharmaceuticals, Inc.'s capital expenditures?
Mirum Pharmaceuticals, Inc. (MIRM) invested $954K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Mirum Pharmaceuticals, Inc. spend on research and development?
Mirum Pharmaceuticals, Inc. (MIRM) invested $186.2M in research and development during fiscal year 2025.
What is Mirum Pharmaceuticals, Inc.'s current ratio?
Mirum Pharmaceuticals, Inc. (MIRM) had a current ratio of 2.67 as of fiscal year 2025, which is generally considered healthy.
What is Mirum Pharmaceuticals, Inc.'s debt-to-equity ratio?
Mirum Pharmaceuticals, Inc. (MIRM) had a debt-to-equity ratio of 1.68 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mirum Pharmaceuticals, Inc.'s return on assets (ROA)?
Mirum Pharmaceuticals, Inc. (MIRM) had a return on assets of -2.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Mirum Pharmaceuticals, Inc.'s P/E ratio?
Mirum Pharmaceuticals, Inc. (MIRM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $5.3B as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Mirum Pharmaceuticals, Inc.'s price-to-sales ratio?
Mirum Pharmaceuticals, Inc. (MIRM) trades at 8.6x sales, its market capitalization divided by revenue of $618.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $5.3B as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Mirum Pharmaceuticals, Inc.'s Altman Z-Score?
Mirum Pharmaceuticals, Inc. (MIRM) has an Altman Z-Score of 5.92, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Mirum Pharmaceuticals, Inc.'s Piotroski F-Score?
Mirum Pharmaceuticals, Inc. (MIRM) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mirum Pharmaceuticals, Inc.'s earnings high quality?
Mirum Pharmaceuticals, Inc. (MIRM) reported a net loss of $23.4M while generating $55.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Mirum Pharmaceuticals, Inc. cover its interest payments?
Mirum Pharmaceuticals, Inc. (MIRM) reported an operating loss of $22.1M against $14.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Mirum Pharmaceuticals, Inc.?
Mirum Pharmaceuticals, Inc. (MIRM) scores 71 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.